Similarly, the CheckMate-9×8 trial randomised patients with metastatic CRC to first-line treatment (without breaks) with oxaliplatin-based chemotherapy and bevacizumab with or without nivolumab, with median PFS of 11.9 months—the percentage of MMR-deficient cases has not been disclosed [26]. This evidence concerns the gene MRC1 and colorectal carcinoma.